Entera Bio Appoints Laura Hamill and Juan Camilo Arjona Ferreira to Board, Effective Dec. 1

Bitget2026/11/06 21:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Entera Bio appointed Laura Hamill, former Gilead worldwide commercial operations executive vice president, to its board effective December 1, 2026.
Juan Camilo Arjona Ferreira, Organon's research and development head and chief medical officer, also joins the board effective December 1, 2026.
Riccardo Paolo Camisasca named chief medical officer, bringing more than 30 years' experience, including leadership roles at Takeda, Novartis and Sumitomo Pharma Switzerland.
Michele McDermott appointed senior vice president, medical affairs; previously Amgen's US bone health medical director.
Ofer Spiegelstein named vice president and early clinical development head; previously Teva's clinical pharmacology and pharmacometrics head.
Graziella Soulban appointed vice president, clinical development and study lead, with prior experience at Sumitomo Pharma America and Myovant Sciences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061615PRIMZONEFULLFEED9871616) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.

华尔街见闻•2026/11/07 07:31

Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"

SpaceX (SPCX.US) undergoes board changes: Google executive departs, Tesla merger evaluation underway.

SpaceX (SPCX.US) announced on Friday that Don Harrison has resigned from the company's board of directors.

智通财经•2026/11/07 06:31

The major cycle's downward structure remains intact, while the minor cycle's rebound lacks volume: Is this a support zone or just a consolidation phase?

AiCoin•2026/11/07 06:03